They observed that anti-CTLA-4 mAbs with the same Fc variants employed in ipilimumab (IgG1) and tremelimumab (IgG2) both induced in vivo depletion of tumour infiltrating Treg cells in the context of human FcγRs, mainly in inflamed tumours with high FcγR-expressing innate effector cells (128). Here, CTLA4 is linked to neoplasm.